JNJ - Johnson & Johnson

NYSE - Nasdaq Real Time Price. Currency in USD
125.8746
-0.9554 (-0.7533%)
As of 3:20PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close126.8300
Open126.9400
Bid126.0600 x 200
Ask126.0800 x 100
Day's Range125.4100 - 127.4600
52 Week Range122.1500 - 148.3200
Volume4,600,150
Avg. Volume8,031,553
Market Cap337.676B
Beta0.59
PE Ratio (TTM)265.56
EPS (TTM)0.4740
Earnings DateJul 17, 2018
Forward Dividend & Yield3.36 (2.57%)
Ex-Dividend Date2018-02-26
1y Target Est145.10
Trade prices are not sourced from all markets
  • Here’s why Amazon won’t go into pharma: hedge fund billionaire
    Yahoo Finance Video5 hours ago

    Here’s why Amazon won’t go into pharma: hedge fund billionaire

    Larry Robbins, CEO of Glenview Capital Management, told investors he doesn’t expect Amazon to move into the drug space. Yahoo Finance’s Alexis Christoforous, Melody Hahm, and Julia La Roche discuss his reasoning.

  • Biktarvy Could Be a Major Driver for Gilead Sciences in 2018
    Market Realist16 minutes ago

    Biktarvy Could Be a Major Driver for Gilead Sciences in 2018

    Gilead Sciences (GILD) is planning to launch a novel HIV drug, Biktarvy, in the United States and Europe in 1H18. On February 7, Gilead secured FDA approval for Biktarvy, which is an unboosted integrase strand transfer inhibitor, bictegravir, combined with a dual nucleoside reverse transcriptase inhibitor backbone, Descovy, as an STR (single tablet regimen) for HIV-1 infected patients. Biktarvy, a differentiated HIV-1 regimen

  • How Johnson & Johnson’s Pharmaceutical Segment Performed in 1Q18
    Market Realist5 hours ago

    How Johnson & Johnson’s Pharmaceutical Segment Performed in 1Q18

    About 49.2% of Johnson & Johnson’s (JNJ) total revenues in 1Q18 came from the pharmaceutical segment, making it the largest revenue contributor for the company. The pharmaceutical business includes revenues from cardiovascular and metabolic products, infectious disease products, immunology products, oncology products, neuroscience products, and pulmonary hypertension products.

  • Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18
    Market Realist6 hours ago

    Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18

    Johnson & Johnson (JNJ) reported 8.4% growth in operating revenues and a 4.2% positive impact of foreign exchange to $20.0 billion in 1Q18 as compared to revenues of $17.8 billion during 1Q17. Johnson & Johnson reported growth across all three of its segments: the pharmaceutical segment, the consumer health segment, and the medical devices segment.

  • Johnson & Johnson’s Revenues Continued to Rise in 1Q18
    Market Realist23 hours ago

    Johnson & Johnson’s Revenues Continued to Rise in 1Q18

    Johnson & Johnson (JNJ) reported 12.6% growth in its revenues to $20.0 billion during 1Q18 as compared to revenues of $17.8 billion during 1Q17. The company surpassed Wall Street analyst estimates for EPS (earnings per share) and revenues and reported EPS of $2.06 on revenues of $20.0 billion during 1Q18 against estimates for EPS of $2.00 on revenues of $19.4 billion during 1Q17.

  • Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings
    Market Realistyesterday

    Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings

    Eli Lilly & Co. (LLY) is a leading US-based pharmaceutical company with a product portfolio covering human health products and animal health products. Eli Lilly is set to release its 1Q18 earnings on April 24.

  • Motley Foolyesterday

    Johnson & Johnson's Top-Line Growth Isn't What It Seems

    The company’s double-digit growth comes with some caveats.

  • Geron Corporation: The Clock Is Ticking
    Motley Foolyesterday

    Geron Corporation: The Clock Is Ticking

    Geron's stock has been a magnet for short-sellers, but the long thesis remains intact.

  • Why GlaxoSmithKline’s 1Q18 Revenues Are Expected to Fall
    Market Realistyesterday

    Why GlaxoSmithKline’s 1Q18 Revenues Are Expected to Fall

    As discussed in the previous article, analysts expect a 2.2% decrease in GlaxoSmithKline’s (GSK) 1Q18 revenues to 7.2 billion pounds due to the impact of divestitures, the negative impact of foreign exchange, and lower sales of some products.